Black Titan Corp BTTC
Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026
Black Titan Corp (BTTC) is a healthcare company listed in the US with a market value of about $5M. In fiscal year 2026 it had revenue of $2M and net income of -$6M, a net margin of -268.1%.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -21%.
About Black Titan
Black Titan is listed in the US and classified in biotechnology: biological products (no diagnostic substances). It was profitable in 2 of the last 3 years in our data.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 3 years
| Fiscal year | 2026 | 2025 | 2024 |
|---|---|---|---|
| Revenue | $2M | $3M | $2M |
| Net income | -$6M | $209911 | $153227 |
| Free cash flow | -$5M | $270793 | $190028 |
| EPS (diluted) | $-0.39 | $0.01 | $0.01 |
| Net margin | -268.1% | 7.8% | 7.2% |
| ROIC | -91.3% | 15.9% | 13.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Black Titan pay a dividend?
Not currently.
Is Black Titan a good stock to buy?
We do not give buy or sell advice. Black Titan scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.